AN2 Therapeutics Reports Q3 2026 Earnings: Net Loss of $8.0 Million and EPS of -$0. ...
Clinical-Stage Biotech Advances Boron-Based Pipeline as Cash Runway Extends Into 2029 Related Stocks: ANTX ,
Clinical-Stage Biotech Advances Boron-Based Pipeline as Cash Runway Extends Into 2029 Related Stocks: ANTX ,